Diabetes regulated anti-inflammatory RNA (DRAIR)

Diabetes regulated anti-inflammatory RNA (DRAIR), previously known as CPEB2 divergent transcript (CPEB2-DT), CPEB2 antisense RNA 1 (CPEB2-AS1), or CPEB2 antisense RNA 1 (head to head), is a long non-coding RNA (lncRNA) divergently transcribed from the CPEB2 gene locus. It is predominantly expressed in the nucleus and highly enriched in chromatin fractions of monocytes and macrophages. DRAIR is downregulated in monocytes from patients with type 2 diabetes and in response to high glucose, palmitic acid, and the inflammatory cytokine IL-1β. It regulates the inflammatory phenotype of monocytes/macrophages by epigenetic mechanisms, such as inhibiting the repressive mark H3K9me2 and interacting with chromatin regions to regulate nearby and distant genes. Overexpression of DRAIR upregulates anti-inflammatory and macrophage differentiation genes while downregulating pro-inflammatory genes. Loss of DRAIR leads to increased inflammation and reduced phagocytosis. These properties position DRAIR as an RNA with potential significance in the regulation of diabetes-associated inflammation, but it is not considered a classic therapeutic target such as a receptor, enzyme, transporter, or protein[1].

Other names

CPEB2 divergent transcriptCPEB2-DTCPEB2 antisense RNA 1 (head to head)CPEB2-AS1DRAIRDiabetes regulated anti-inflammatory RNA